Cancer treatment
The invention relates generally to the treatment of cancer. One embodiment of the invention provides a method of treating cancer in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
1. In a method of treating a patient diagnosed with cancer with trichostatin A (TSA), the improvement comprising:
selecting for treatment a patient determined to have increased aurora kinase A (AURKA) expression,
wherein the treating includes administering TSA to the selected patient in an amount sufficient to decrease an AURKA level in the selected patient.
2. The improvement of claim 1 , wherein the amount of TSA is sufficient to inhibit histone deacetylase (HDAC) activity in the selected patient.
3. The improvement of claim 1 , wherein the amount of TSA is between about 0.1 mg/kg/day and about 10 mg/kg/day.
4. The improvement of claim 3 , wherein the amount of TSA is between about 0.5 mg/kg/day and about 5 mg/kg/day.
5. The improvement of claim 1 , wherein the cancer is selected from a group consisting of: breast cancer, gastric cancer, colon cancer, rectal cancer, bladder cancer, pancreatic cancer, ovarian cancer, prostate cancer, lung cancer, hematological cancer, and skin cancer.
6. The improvement of claim 1 , wherein the TSA is administered orally.
7. The improvement of claim 1 , wherein the TSA is administered intravenously.
8. The improvement of claim 1 , further comprising:
determining, from a tumor sample obtained from the selected patient's body, a level of aurora kinase A (AURKA) expression.
9. The improvement of claim 1 , wherein the cancer is breast cancer.
10. The improvement of claim 1 , wherein the cancer is a malignancy.